What Lukastma Treats: Main Uses and Benefits

Lukastma is a maintenance medication primarily focused on providing sustained control and support for conditions involving inflammatory or irritative processes and symptoms that interfere with daily functioning affecting the airways. Its applications include managing symptoms associated with asthma and allergic rhinitis.

It is commonly used to help with symptoms across key domains, including the long-term control of persistent asthma, relief of symptoms from both seasonal and perennial allergic rhinitis, and acute prevention of exercise-induced breathing difficulty (EIB). The medication plays a role in managing the symptomatic burden associated with these recurring issues.

In clinical scenarios, Lukastma is commonly used to help with persistent symptoms, such as wheezing, night-time coughing, nasal congestion, and sneezing. The therapeutic benefit is centered on continuous symptom management, which contributes to easing the overall symptom load and assists with maintaining functional stability when symptoms are more noticeable.

---

Quick Fact: Support for Symptoms of Irritative States Lukastma is applied in addressing symptom clusters that may become intense or disruptive, supporting the patient during difficult episodes by easing distress and managing symptoms related to heightened physiological activity in the respiratory system.

Regulatory References

1. NIH MedlinePlus overview

Lukastma is a maintenance medication with specific eligibility criteria defined by regulatory bodies across age, known allergies, and certain medical conditions.

Populations for Whom Use is Restricted or Prohibited

Classification	Eligibility Rule
Contraindication	The drug is prohibited for patients with known hypersensitivity to the active ingredient (Montelukast) or any of the formulation’s components.
Non-Indication	Lukastma is not indicated for use in reversing bronchospasm during acute asthma attacks or status asthmaticus; it is reserved for chronic, prophylactic treatment.
Genetic/Metabolic	The chewable tablet forms contain phenylalanine and are therefore restricted for use in patients with phenylketonuria (PKU).

Age-Group Eligibility Rules

Official eligibility is specific to the patient's age and the condition being managed:

• Adults and Adolescents (15 years): Eligible for all approved maintenance uses.
• Pediatric Patients: Eligibility begins at 12 months for asthma prophylaxis, 6 months for perennial allergic rhinitis, and 6 years for the prevention of exercise-induced bronchoconstriction. Use is not established below these minimum age thresholds for each specific indication.
• Older Adults: No dosage adjustment is recommended, as safety and effectiveness are comparable to younger adults.

Condition-Specific Eligibility

• Renal Impairment: No dosage adjustment is recommended for patients with renal insufficiency, as the drug is primarily eliminated via bile.
• Hepatic Impairment: No dosage adjustment is needed for mild-to-moderate hepatic insufficiency. However, use status has not been evaluated or established in patients with severe hepatic impairment.

Pregnancy and Lactation Status

• Use during pregnancy and lactation is generally restricted and is only permitted if considered clearly essential by the prescribing authority.

The official interaction profile for Lukastma is defined by documented pharmacokinetic (PK) and pharmacodynamic (PD) patterns, as detailed in government regulatory sources.

Metabolic and Exposure Interactions

Lukastma is primarily metabolized by Cytochrome P450 enzymes 2C8, 2C9, and 3A4. A clinically relevant PK interaction occurs when co-administered with the enzyme inhibitor Gemfibrozil, which is documented to increase the systemic exposure of Lukastma by approximately 4.4-fold. Conversely, co-administration with enzyme inducers such as Rifampicin, Phenobarbital, and Phenytoin may potentially decrease Lukastma plasma concentrations, and the official label notes that caution is required. Conversely, studies document that Montelukast does not have clinically important effects on the systemic exposure of several co-administered drugs, including Theophylline, Digoxin, and Warfarin.

Pharmacodynamic Restrictions

Official regulatory restrictions mandate that patients with known aspirin sensitivity must continue to avoid aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) while using Lukastma. The drug should also not be abruptly substituted for oral or inhaled corticosteroids.

Food and Administration Timing

The regulatory documentation includes specific timing rules for the oral granule formulation; if mixed with certain soft foods (such as applesauce, rice, carrots, or ice cream), the dose must be administered within 15 minutes of mixing. The label also advises that the potential for dizziness or drowsiness may be worse if taken concurrently with alcohol.

Lukastma (Montelukast) functions by providing a targeted mechanistic blockade against specific inflammatory mediators, disrupting a key biochemical cascade.

Targeted Antagonism of the CysLT1 Receptor

Lukastma acts as a selective antagonist of the Cysteinyl Leukotriene Receptor Type 1 (mathbfCysLT1), which is prevalent on airway smooth muscle and inflammatory cells. By occupying this receptor site, the molecule halts the signal initiated by the endogenous inflammatory mediators, the cysteinyl leukotrienes (LTD4), preventing them from activating their cellular targets.

Modulation of Inflammatory and Smooth Muscle Signals

This receptor blockade initiates two primary physiological outcomes: it limits the leukotriene-driven increase in vascular permeability, resulting in attenuation of airway edema and swelling. Concurrently, the mechanism indirectly prevents the leukotriene-mediated contraction of the bronchial smooth muscle. This continuous dual action affects the signaling of inflammation and smooth muscle excitation, modulating the inherent responsiveness of the airways.

Constraints of Mechanism Specificity

The drug's high specificity to the leukotriene pathway means its mechanism is confined to modulating processes driven by CysLTs, and it does not affect pathways mediated by other rapid-onset mediators like histamine. Consequently, the mechanism facilitates sustained modulation of the CysLT pathway but is functionally unable to provide the rapid reversal of muscle contraction necessary to override non-CysLT mediated bronchoconstrictive signals.

How to Use Lukastma: Official Administration Guidelines

Lukastma is an oral medicine intended for long-term, continuous prophylactic use. Its administration pattern is defined by adherence to dose, frequency, and specific timing for optimal maintenance. It is explicitly not intended for use in acute asthma attacks; appropriate rescue medication must be available.

The standard pattern is to take the medicine once daily. For the ongoing management of chronic asthma or when treating both asthma and allergic rhinitis, the dose should be taken in the evening. If the medicine is being used solely for allergic rhinitis, the time of administration may be flexible.

---

Patient Age Group	Dosage Strength	Frequency & Timing
Adults 15 years	10 mg (Film-coated tablet)	Once daily, preferably evening (Asthma/Combined)
Pediatric 6–14 years	5 mg (Chewable tablet)	Once daily, evening
Pediatric 12 mos–5 years	4 mg (Chewable tablet or Granules)	Once daily, evening

---

Administration Requirements

The medicine is designed for daily intake and should not be discontinued even when symptoms are fully controlled. Tablets and chewable tablets may be taken with or without food. Chewable tablets must be fully chewed before swallowing.

Oral granules require precise handling: the entire contents of the packet must be mixed with a specified soft food or liquid (e.g., applesauce) and administered completely within 15 minutes of opening. If a dose is missed, patients should resume the schedule with the next dose; doubling the dose is not permitted.

Evidence for use in Persistent Asthma Management

Lukastma was studied for its role as a controller therapy for chronic, persistent asthma primarily through short-term and long-term Randomized Controlled Trials (RCTs). These studies examined changes in lung function (FEV1) and monitored the evolution of symptoms, such as nocturnal coughing, alongside the frequency of acute asthma episodes. Trials report how symptoms evolved in the observed populations, and studies described the medicine’s inclusion in treatment regimens. Findings varied across comparisons against other standard long-term controller therapies.

---

Evidence for the Prevention of Exercise-Induced Breathing Difficulty

Lukastma was evaluated in research exploring short-term symptom changes related to breathing difficulty triggered by physical activity (EIB). Acute RCTs used standardized exercise challenges to monitor the change in lung function following exertion. These studies contributed data related to acute, short-term functional response, but follow-up durations were limited for continuous daily use in EIB prevention.

---

Evidence for the Relief of Allergic Rhinitis Symptoms

For the relief of allergic rhinitis symptoms, short-term RCTs examined outcomes related to physical discomfort, such as nasal congestion and sneezing. Findings describe patterns observed where symptom scores evolved in comparison to placebo. The evidence base describes that comparative evidence is limited when assessed against other treatments for allergic rhinitis.

---

Evidence Gaps and Areas of Research Uncertainty

Research has been evaluated in special populations, including pediatric patients, but data for certain groups, such as the elderly, remain insufficient. The long-term effects are not fully established, particularly concerning comparative performance against other long-term controller medicines over several years. This research contributes to the broader evidence landscape, but evidence quality varies across studies, and data are still emerging in several areas.

Common questions about Lukastma (FAQ)

---

Q: Will this medicine make me feel sleepy?

Official product information for pregabalin (the active ingredient in Lukastma) states that dizziness and somnolence (sleepiness) are common side effects. Patients are advised to consider that these effects may potentially impair the ability to drive or operate complex machinery.

---

Q: Can I drink alcohol while taking this medication?

Regulatory documents indicate that combining this medication with alcohol is not advised. Combining pregabalin with alcohol can increase the risk of certain side effects, such as heightened sleepiness and dizziness, as they may enhance each other's effects.

---

Q: Is it safe to take this drug for long-term conditions?

The medication is approved for the management of chronic conditions, such as certain types of neuropathic pain and fibromyalgia. Official information details potential serious adverse reactions, such as angioedema (severe swelling), that may occur at any time during treatment, requiring close attention throughout use.

---

Q: Can children who are 2 years old use this medicine?

Official labeling states that for the use as adjunctive therapy for partial-onset seizures, the product is indicated for patients 1 month of age and older. However, for indications such as pain conditions or fibromyalgia, it may not be approved for this very young age group. Use in children is limited to certain approved conditions and specific age ranges.

Lukastma (montelukast sodium) must be stored under specific conditions defined in regulatory labeling to maintain its stability and effectiveness.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature (20^circmathrmC to 25^circmathrmC), with permissible excursions between 15^circmathrmC and 30^circmathrmC.
Protection	Must be stored in the original container and protected from light and moisture.

Child Safety: The medication must be kept out of the reach of children.

Disposal Instructions

Official regulatory guidelines require that any unused or expired Lukastma product be disposed of strictly according to local requirements. The product should not be flushed down a toilet or poured down a drain unless specifically advised by local regulations.